3 Stocks Pushing The Health Services Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 122 points (0.7%) at 17,066 as of Monday, July 14, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,069 issues advancing vs. 930 declining with 155 unchanged.

The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.5%. Top gainers within the industry include Grifols ( GRFS), up 2.4%, Cigna ( CI), up 1.6%, Abbott Laboratories ( ABT), up 1.0% and Aetna ( AET), up 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Edwards Lifesciences ( EW) is one of the companies pushing the Health Services industry lower today. As of noon trading, Edwards Lifesciences is down $1.44 (-1.6%) to $86.50 on light volume. Thus far, 366,794 shares of Edwards Lifesciences exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $86.38-$88.34 after having opened the day at $88.34 as compared to the previous trading day's close of $87.94.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Lifesciences has a market cap of $9.3 billion and is part of the health care sector. Shares are up 33.7% year-to-date as of the close of trading on Friday. Currently there are 10 analysts that rate Edwards Lifesciences a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Edwards Lifesciences as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Edwards Lifesciences Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Edwards Lifesciences: Cramer's Top Takeaways

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Edwards Lifesciences Is Not Skipping A Beat

Canaccord Says Edwards Lifesciences Is Its Favorite Med Tech Stock